Walt KowtoniukPrincipal at Third Rock Ventures
Walt is a company creator with nearly a decade of experience working at the intersection of strategy and science. At Third Rock, Walt focuses on discovering, launching, and building companies aimed at treating rare genetic diseases and transforming the lives of patients. He first joined Third Rock in 2013 as a senior associate and returned in 2018 as a principal. Walt was involved in the launch of Fulcrum Therapeutics and Goldfinch Bio. Walt was integral in the creation and building of Fulcrum Therapeutics, joining the company full time to lead strategy, business development, and operations. As part of the leadership team, he was involved in advancing the pipeline to its first clinical candidate and growing the company to 40+ employees. Walt has also worked in strategy consulting with Clarion Healthcare developing new business strategies and providing commercial insight into early product development in the rare disease space. He has a Ph.D. in chemical biology from Harvard University and a B.S. in biochemistry, molecular biology, and philosophy from Gettysburg College. Walt is also a member of Corporate Advisory Council for National Tay-Sachs and Allied Diseases (NTSAD).